Currently, first line treatment fails for up to two thirds of cancer patients, and it takes up to 6 months to realize. We think there is a better way. The LiMiTeR trial is an ongoing effort to profile cancer liquid biopsies during treatment. Data are used to help us predict how tumors evolve in response to treatment and how we can adapt our treatment strategies for the best patient outcome.
We are currently running studies for longitudinal treatment monitoring in the USA, Europe, and Asia. These studies focus on the analysis of circulating cell-free DNA in a patient's blood. LiMiTeR uses these liquid biopsies for the identification of biomarkers of response and early detection of resistance in cancer patients. We also use this data to power our AI algorithm for predicting tumor evolution over time and in response to therapy. This project empowers oncologists to be more confident in treatment decision making and to be proactive rather than reactive when it comes to treatment planning.